The shares have continued to exhibit weakness post the results which always represents a doubt in your mind if you have not missed anything. Having read and re-read the statement, today I have added even more at £11.85. The shares are fairly illiquid and could move on small volume(as have done in the past). I […]
Both reported results yesterday. AMS results were in line and there weren’t any notable points worth commenting on. Distribution finance had excellent results, both reduction in arrears as well as increase in the overall loan book. I have added some more at 58p, having sold some at 54p a few months earlier as I was […]
One of my top holdings had half year results. The shares have very limited newsflow, so I was looking forward to the statement as this is the only time you get an insight in what is going on inside the company. I like the chairman’s statements from them, they are no nonsense, old school type […]
While there is a lot of noise in the market, for those of you who want to buy and hold their positions for a few years, here is a list of my top 10 in alphabetical order. One thing to notice is the large portion of US names, despite me investing in the UK for […]
First of all, Happy New Year to all investors out there. Hope 2026 brings you lots of success. So on to the update for Q4 and a few thoughts on 2025. The porfolio performed reasonably well during Q4, delivering average return of 2.8% vs negative 2.2% for FTSE AIMs and 2.6% for S&P500. A few […]
One of the names which I initiated positions in a couple of months ago(Advanced Medical Solutions) had a bid speculation today. This is not at all surprising as they had one earlier in the year too. Clearly there are a lot of private equity shops lurking around trying to take out solid undervalued UK AIMs […]
Over the last couple of weeks I initiated a position in Ondine Biomedical(OBI). Ondine is a s a Canadian life sciences company focused on developing and commercializing light-based, non-antibiotic antimicrobial therapies to prevent and treat infections in hospitals and other settings. Its core platform, called photodisinfection, uses a photosensitive agent activated by light to rapidly […]
While I no longer hold them, I still follow them closely for potential entry. Both had reasonable updates(revenue growth more than profitability) as the NIC contributions are starting to bite into these labour intensive sectors. I am keenly following what will come out of the budget as there is significant speculation that there will be […]
Generally good update. The business is doing well in a challenging environment, but the fact that they have production facilities in multiple countries helps a lot with the tariff malarkey. None the less, I sold about 1/3 of my shares on the day, as usually Volex rallies strongly on results and then sells off(I am […]
Yesterday(20th Nov), Mitie updated the market with its H1 26 results. I thought the results were excellent (organic revenue growth of 6.4%, overall growth of 10.4%), with all levels growing despite increases in costs(NIC) which I suspect over the long term would roll over into pricing as contracts renew. The pipeline seems excellent(bidding pipeline is […]